Bruton’s酪氨酸激酶抑制剂的研究进展

被引:3
作者
姜海龙 [1 ]
赵兴俄 [2 ]
金秋 [2 ]
唐锋 [2 ]
李文赟 [3 ]
魏清筠 [1 ]
姚其正 [1 ]
机构
[1] 中国药科大学药学院
[2] 江苏先声药业有限公司
[3] 四川抗菌素工业研究所
关键词
Btk; 抑制剂; 结构; 临床研究;
D O I
10.13461/j.cnki.wna.004709
中图分类号
R97 [药品];
学科分类号
1007 ;
摘要
Btk(Bruton’s tyrosine Kinase)是一种胞浆蛋白,属于Tec酪氨酸激酶家族,参与调控B细胞的增殖、分化与凋亡,并在多个信号通路中扮演重要的角色。Btk在肿瘤与炎症的发生、发展过程中具有重要作用,因此针对肿瘤治疗与炎症控制而开发的小分子Btk抑制剂受到越来越多的关注。本文综述了Btk抑制剂及其临床研究进展,为合理开发Btk抑制剂提供启示。
引用
收藏
页码:49 / 57
页数:9
相关论文
共 6 条
[1]   Bruton酪氨酸激酶Btk的生物学特性研究进展 [J].
李庆伟 ;
芦静 ;
刘欣 .
辽宁师范大学学报(自然科学版), 2010, 33 (01) :90-95
[2]  
Imidazo[1,5- a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis[J] . Kyung-Hee Kim,Andreas Maderna,Mark E. Schnute,Martin Hegen,Shashi Mohan,Joy Miyashiro,Laura Lin,Evelyn Li,Sean Keegan,Jennifer Lussier,Christopher Wrocklage,Cheryl L. Nickerson-Nutter,Arthur J. Wittwer,Holly Soutter,Nicole Caspers,Seungil Han,Ravi Kurumbail,Kyri Dunussi-Joannopoulos,John Douhan,Allan Wissner.Bioorganic & Medicinal Chemistry Letters . 2011 (21)
[3]   Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity [J].
Uckun, Fatih M. ;
Qazi, Sanjive .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2010, 20 (11) :1457-1470
[4]  
Primary B Cell Immunodeficiencies: Comparisons and Contrasts[J] . Mary Ellen Conley,A. Kerry Dobbs,Dana M. Farmer,Sebnem Kilic,Kenneth Paris,Sofia Grigoriadou,Elaine Coustan-Smith,Vanessa Howard,Dario Campana.Annual Review of Immunology . 2009
[5]  
Bruton's tyrosine kinase together with PI 3-kinase are part of Toll-like receptor 2 multiprotein complex and mediate LTA induced Toll-like receptor 2 responses in macrophages[J] . M. Liljeroos,R. Vuolteenaho,S. Morath,T. Hartung,M. Hallman,M. Ojaniemi.Cellular Signalling . 2006 (3)
[6]   Tyrosine phosphorylation enhances the SH2 domain-binding activity of Bcr and inhibits Bcr interaction with 14-3-3 proteins [J].
Peters, KL ;
Smithgall, TE .
CELLULAR SIGNALLING, 1999, 11 (07) :507-514